Steven Lefkowitz Net Worth

The estimated Net Worth of Steven W Lefkowitz is at least 1.1 百万$ dollars as of 16 November 2023. Mr. Lefkowitz owns over 15,000 units of CorMedix Inc stock worth over 521,691$ and over the last 13 years he sold CRMD stock worth over 399,140$. In addition, he makes 181,300$ as Independent Director at CorMedix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lefkowitz CRMD stock SEC Form 4 insiders trading

Steven has made over 12 trades of the CorMedix Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of CRMD stock worth 33,750$ on 16 November 2023.

The largest trade he's ever made was buying 135,416 units of CorMedix Inc stock on 12 December 2017 worth over 65,000$. On average, Steven trades about 13,060 units every 118 days since 2011. As of 16 November 2023 he still owns at least 75,498 units of CorMedix Inc stock.

You can see the complete history of Mr. Lefkowitz stock trades at the bottom of the page.

Steven Lefkowitz biography

Steven W. Lefkowitz is an Independent Director of CorMedix Inc. He was reappointed to the Board in June 2017. He also served as our acting Chief Financial Officer from August 2013 to July 2014. Mr. Lefkowitz has been the President and Founder of Wade Capital Corporation, a financial advisory services company, since June 1990. Mr. Lefkowitz has been a director of both public and private companies. Mr. Lefkowitz received his A.B. from Dartmouth College in 1977 and his M.B.A. from Columbia University in 1985. Among other experience, qualifications, attributes and skills, Mr. Lefkowitz’s education, experience and financial expertise led to the conclusion of our Board that he should serve as a director of our Company in light of our business and structure.

What is the salary of Steven Lefkowitz?

As the Independent Director of CorMedix Inc, the total compensation of Steven Lefkowitz at CorMedix Inc is 181,300$. There are 10 executives at CorMedix Inc getting paid more, with Khoso Baluch having the highest compensation of 1,795,830$.

How old is Steven Lefkowitz?

Steven Lefkowitz is 63, he's been the Independent Director of CorMedix Inc since 2014. There are 7 older and 6 younger executives at CorMedix Inc. The oldest executive at CorMedix Inc is John L. Armstrong Jr., 76, who is the Exec. VP for Technical Operations.

What's Steven Lefkowitz's mailing address?

Steven's mailing address filed with the SEC is C/O CORMEDIX INC.,, 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at CorMedix Inc

Over the last 15 years, insiders at CorMedix Inc have traded over 693,980$ worth of CorMedix Inc stock and bought 2,651,866 units worth 3,532,566$ . The most active insiders traders include Mehmood Khan、Gary A. Gelbfish、Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of 199,105$. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth 50,718$.

What does CorMedix Inc do?

cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.

Complete history of Mr. Lefkowitz stock trades at CorMedix Inc

CorMedix Inc executives and stock owners

CorMedix Inc executives and other stock owners filed with the SEC include:

• Khoso Baluch,
  Chief Executive Officer, Interim Principal Accounting Officer, Director
• Phoebe Mounts,
  Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal
• Elizabeth Masson,
  Executive Vice President - Head of Clinical Operations
• Khoso Baluch,
  CEO & Director
• Dr. Phoebe Mounts Esq.,
  Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal
• John Armstrong,
  Executive Vice President - Technical Operations
• Elizabeth Masson-Hurlburt,
  Exec. VP & Head of Clinical Operations
• John L. Armstrong Jr.,
  Exec. VP for Technical Operations
• Alan Dunton,
  Independent Director
• Myron Kaplan,
  Independent Chairman of the Board
• Steven Lefkowitz,
  Independent Director
• Janet Dillione,
  Independent Director
• Gregory Duncan,
  Director
• Paulo Costa,
  Director
• Matthew David,
  Chief Financial Officer, Executive Vice President
• Thomas Nusbickel,
  Exec. VP & Chief Commercial Officer
• Dr. Paul Chew M.D.,
  Acting Chief Medical Officer
• Dr. Paul Chew,
  Acting Chief Medical Officer
• Dr. Matthew T. David M.D.,
  Exec. VP & CFO
• Judith R Abrams,
  Chief Medical Officer
• Robert W. Cook,
  Chief Financial Officer
• Taunia Markvicka,
  Director
• Antony Pfaffle,
  Director
• Randy Milby,
  Chief Operating Officer
• Cora M Tellez,
  Director
• Mehmood Khan,
  
• Michael W George,
  Director
• Gary A. Gelbfish,
  Director
• James Lefkowitz,
  Director
• Bami Bastani,
  Director
• Timothy M Hofer,
  Secretary
• Mark T. Houser,
  Chief Medical Officer
• John C. Houghton,
  President and CEO
• Mark A. Klausner,
  Chief Medical Officer
• Russell H Ellison,
  Director
• Robert A Stewart,
  
• Matthew Duffy,
  Director
• Harry O'grady,
  Chief Financial Officer
• Richard Cohen,
  Director
• Development Inc Pharmabio,
  10% owner
• Brian Lenz,
  Chief Financial Officer
• Thomas Nusbickel,
  EVP, Chief Commercial Officer
• Joseph Todisco,
  Chief Executive Officer
• Kaufman Beth Zelnick,
  Chief Legal Officer
• Erin Mistry,
  Chief Commercial Officer